TS
TSTL.LSE Tristel
- Market cap
- GBX 195M
- P/E
- 23.8x
- P/B
- 5.45x
- ROE
- 22.4%
- Dividend yield
- 3.51%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is TSTL.LSE undervalued?
Graham numberTSTL.LSE trades 140.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Tristel fundamental analysis
No fundamental analysis for Tristel yet.
Tristel stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Tristel
Tristel plc develops, manufactures, and sells infection prevention products in the United Kingdom, Australia, Germany, Western Europe, and internationally. The company operates through three segments: Hospital Medical Device Decontamination, Hospital Environmental Surface Disinfection, and Other. It offers device decontamination products, including wipes system, ULT, OPH, Stella system, fuse for Stella, rinse assure, clean, EVE, medistel, EVA system, daisygrip, fuse for surf…
Full company profileTristel financial statements
Tristel annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 20.3M | 22.2M | 26.2M | 31.7M | 31.0M | 31.1M | 36.0M | 41.9M | 46.5M | 51.1M |
| Gross Profit | 15.7M | 17.2M | 20.7M | 25.2M | 24.7M | 24.7M | 29.2M | 33.6M | 37.9M | 39.3M |
| Operating Income | 3.90M | 3.98M | 4.70M | 6.81M | 4.76M | 4.20M | 5.28M | 6.98M | 8.40M | 11.0M |
| EBITDA | 5.19M | 5.50M | 6.17M | 9.30M | 6.70M | 4.46M | 7.90M | 10.0M | 11.5M | 14.3M |
| Net Income | 3.42M | 3.27M | 4.03M | 5.10M | 3.66M | 987K | 4.46M | 6.49M | 6.64M | 7.98M |
| EPS | 0.08 | 0.07 | 0.09 | 0.11 | 0.08 | 0.02 | 0.09 | 0.14 | 0.14 | 0.17 |
| Balance Sheet | ||||||||||
| Total Assets | 20.1M | 22.5M | 28.5M | 40.9M | 39.9M | 38.7M | 41.4M | 44.1M | 45.3M | 48.3M |
| Total Liabilities | 4.05M | 4.11M | 5.13M | 12.5M | 9.85M | 9.75M | 10.7M | 11.7M | 12.3M | 12.6M |
| Shareholders' Equity | 16.1M | 18.4M | 23.4M | 28.5M | 30.1M | 29.0M | 30.7M | 32.4M | 33.0M | 35.7M |
| Cash & Short-term Investments | 5.09M | 6.66M | 4.17M | 6.21M | 8.09M | 8.88M | 9.55M | 11.8M | 12.8M | 16.0M |
| Total Debt | - | - | - | 6.00M | 5.91M | 5.81M | 5.18M | 5.86M | 5.88M | 5.86M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 4.35M | 4.50M | 5.49M | 6.99M | 6.48M | 5.55M | 8.49M | 10.9M | 10.3M | 11.5M |
| Capital Expenditure | 1.00M | 1.51M | 1.35M | 2.38M | 1.77M | 1.20M | 2.42M | 1.14M | 857K | 683K |
| Free Cash Flow | 3.35M | 2.98M | 4.14M | 4.61M | 4.71M | 4.35M | 6.07M | 10.1M | 9.46M | 10.8M |
| Ratios | ||||||||||
| ROE | 21.3% | 17.8% | 17.3% | 17.9% | 12.2% | 3.4% | 14.5% | 20.0% | 20.1% | 22.4% |
| ROA | 17.0% | 14.5% | 14.1% | 12.5% | 9.2% | 2.5% | 10.8% | 14.7% | 14.6% | 16.5% |
| Net Profit Margin | 16.9% | 14.7% | 15.4% | 16.1% | 11.8% | 3.2% | 12.4% | 15.5% | 14.3% | 15.6% |
| Debt to Equity | - | - | - | 0.21x | 0.20x | 0.20x | 0.17x | 0.18x | 0.18x | 0.16x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Tristel dividends
- Dividend yield
- 3.51%
- Forward dividend
- 0.14 GBX
- Payout ratio
- 85.1%
- Ex-dividend date
- Nov 26, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | 6.79M | 0.14 | 85.1% |
| 2025 | GBP 6.66M | 0.14 | 100.3% |
| 2024 | GBP 6.22M | 0.13 | 95.9% |
| 2023 | GBP 4.51M | 0.10 | 101.1% |
| 2022 | GBP 3.09M | 0.06 | 313.2% |
| 2021 | GBP 3.02M | 0.06 | 82.5% |
| 2020 | GBP 2.62M | 0.06 | 51.4% |
| 2019 | GBP 2.21M | 0.05 | 54.8% |
| 2018 | GBP 1.82M | 0.04 | 55.6% |
| 2017 | GBP 2.79M | 0.06 | 81.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Tristel
- Insiders 2.36%
- Institutions 48.60%
- Public & others 49.04%
- Shares outstanding 48.1M
- Free float 46.3M
Tristel company profile
- Company name
- Tristel
- Ticker
- TSTL.LSE
- ISIN
- GB00B07RVT99
- Exchange
- London Exchange
- Listed since
- Jun 1, 2005
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 282
- Fiscal year end
- June
- Address
- Lynx Business Park, Snailwell, United Kingdom, CB8 7NY
- Phone
- 44 16 3872 1500
- Website
- tristel.com
About Tristel
Tristel plc develops, manufactures, and sells infection prevention products in the United Kingdom, Australia, Germany, Western Europe, and internationally. The company operates through three segments: Hospital Medical Device Decontamination, Hospital Environmental Surface Disinfection, and Other. It offers device decontamination products, including wipes system, ULT, OPH, Stella system, fuse for Stella, rinse assure, clean, EVE, medistel, EVA system, daisygrip, fuse for surfaces, dosing system, airstel, enzystel, DOK, pre-clean wipes, rinse wipes, sporicidal wipes, clean for Stella, protect, and wipes; surface disinfection products, such as FUSE, JET, JET LUX, JET PRO, TANK 10 CLO2, TANK 5 CLO2, and TILT 5 CLO2; as well as operates 3T, a cloud-based platform alternative to paper-based traceability systems. The company provides its medical disinfection products, including airway management, cardiology, ear, nose and throat, endoscopy, gastrointestinal physiology, laboratory, ophthalmology, phlebotomy, reproductive health/IVF, surface, ultrasound, urology, women's health, and other products under the Tristel brand. Tristel plc was founded in 1993 and is headquartered in Snailwell, the United Kingdom.
Tristel management
5- Mr. Christopher Paul LeeCEO & Director · born 1962
- Ms. Anna Katarzyna WasylCFO & Director · born 1980
- Emily DaveyGlobal Marketing Director
- Aimee ScarbrowHuman Resources Director
- Julija ShabanovaExecutive Director